@FierceBiotech: Bristol-Myers snapping up Amira Pharma for $325M. Item | Follow @FierceBiotech
@JohnCFierce: Government pledging to overhaul rules on human research. From the NYT. Story | Follow @JohnCFierce
@RyanMFierce: John Halamka has a very lucid explanation for why Harvard Med School needs a full time CIO, NGS demands, storage, etc. Blog post | Follow @RyanMFierce
@MaureenFierce: FDA rejects new use for J&J immune disorder drug Simponi. News | Follow @MaureenFierce
> Aegerion Pharmaceuticals reports that it has recruited Bristol-Myers Squibb veteran Dr. Mark Sumeray as its new chief medical officer. The biotech added that one of its board members plans to resign. Story
> Germany's Cevec Pharmaceuticals says that it has raised $8.5 million in new venture cash to back its vaccines platform. Cevec release
> Australia's QRxPharma says it has raised A$35 million following its NDA for a new combo pain therapy. Release
Pharma News
@FiercePharma: Merck amps up in China with Simcere JV. Report | Follow @FiercePharma
> J&J blockbuster hopefuls get EMA recommendation More
> Roche, Novartis cancer meds win EMA approval Item
> Teva gets a taste of its own patent-challenged medicine Article
> Will pharma fight Express-Medco deal? Story
> Forest taps lobbyist to aid Solomon at HHS News
Biotech IT News
> FDA data analysis reveals adverse drug combo. Article
> Harvard Med School CIO Halamka exiting big job. Story
> Biomax Informatics expands deal with Royal DSM. More
> Mayo Clinic eyes future trial recruitment with health data exchanges. Report
> Bioinformatics upstart Intervention Insights secures $7.2M. Article
Medical Device News
> Nevro lands $58M for pain devices. More
> St. Jude to cut 450 Swedish Jobs. Report
> King's College spins out Centron Diagnostics. Story
> Imperial Innovations invests $6.5M in Stanmore Implants. Article
> Drew Medical's Dinkel banned from Medicare business. News
And Finally... Investigators say that a U.S. study of a Japanese herbal remedy for hot flashes failed to demonstrate the same benefits reported in Japan, where it is a regulated pharmaceutical. TU-025 is a mixture of cinnamon bark, peach pit and botanicals. Story